vegas slot game

vegas slot game GLOBALISATION AND IDENTITY: Australian scholar advocates unified, inclusive path forward

Arcadia Biosciences ( NASDAQ:RKDA – Get Free Report ) and Oriental Rise Holdings Limited Ordinary Shares ( NASDAQ:ORIS – Get Free Report ) are both small-cap basic materials companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership. Institutional and Insider Ownership 17.7% of Arcadia Biosciences shares are owned by institutional investors. 1.8% of Arcadia Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Earnings and Valuation This table compares Arcadia Biosciences and Oriental Rise Holdings Limited Ordinary Shares”s top-line revenue, earnings per share and valuation. Analyst Recommendations This is a summary of current ratings and price targets for Arcadia Biosciences and Oriental Rise Holdings Limited Ordinary Shares, as reported by MarketBeat. Arcadia Biosciences presently has a consensus price target of $6.00, indicating a potential downside of 1.80%. Given Arcadia Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Arcadia Biosciences is more favorable than Oriental Rise Holdings Limited Ordinary Shares. Profitability This table compares Arcadia Biosciences and Oriental Rise Holdings Limited Ordinary Shares’ net margins, return on equity and return on assets. Summary Arcadia Biosciences beats Oriental Rise Holdings Limited Ordinary Shares on 7 of the 12 factors compared between the two stocks. About Arcadia Biosciences ( Get Free Report ) Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas. About Oriental Rise Holdings Limited Ordinary Shares ( Get Free Report ) Oriental Rise Holdings Limited engages in planting, cultivating, processing, and selling processed tea in Mainland China. It offers processed white tea, black tea, and refined tea products to wholesale distributors and end-user retail customers. The company was incorporated in 2019 and is based in Ningde, China. Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter .

The press freedom group Reporters Without Borders is urging Apple to remove its newly introduced artificial intelligence feature that summarizes news stories after it produced a false headline from the BBC. The backlash comes after a push notification created by Apple Intelligence and sent to users last week falsely summarized a BBC report that Luigi Mangione, the suspect behind the killing of the UnitedHealthcare chief executive, had shot himself. The BBC reported it had contacted Apple about the feature “to raise this concern and fix the problem,” but it could not confirm if the iPhone maker had responded to its complaint. On Wednesday, Reporters Without Borders technology and journalism desk chief Vincent Berthier called on Apple “to act responsibly by removing this feature.” “A.I.s are probability machines, and facts can’t be decided by a roll of the dice,” Berthier said in a statement . “The automated production of false information attributed to a media outlet is a blow to the outlet’s credibility and a danger to the public’s right to reliable information on current affairs.” More broadly, the journalist body said it is “very concerned about the risks posed to media outlets by new A.I. tools, noting that the incident emphasizes how A.I. remains “too immature to produce reliable information for the public, and should not be allowed on the market for such uses.” “The probabilistic way in which A.I. systems operate automatically disqualifies them as a reliable technology for news media that can be used in solutions aimed at the general public,” RSF said in a statement. In response to the concerns, the BBC said in a statement, “it is essential to us that our audiences can trust any information or journalism published in our name and that includes notifications.” Apple did not respond to a request for comment. Apple introduced its generative-AI tool in the US in June , touting the feature’s ability to summarize specific content “in the form of a digestible paragraph, bulleted key points, a table, or a list.” To streamline news media diets, Apple allows users across its iPhone, iPad, and Mac devices to group notifications, producing a list of news items in a single push alert. Since the AI feature was launched to the public in late October, users have shared that it also erroneously summarized a New York Times story , claiming that Israeli Prime Minister Benjamin Netanyahu had been arrested. In reality, the International Criminal Court had published a warrant for Netanyahu’s arrest, but readers scrolling their home screens only saw two words: “Netanyahu arrested.” The challenge with the Apple Intelligence incident stems from news outlets’ lack of agency. While some publishers have opted to use AI to assist in authoring articles, the decision is theirs. But Apple Intelligence’s summaries, which are opt-in by the user, still present the synopses under the publisher’s banner. In addition to circulating potentially dangerous misinformation, the errors also risk damaging outlets’ credibility. Apple’s AI troubles are only the latest as news publishers struggle to navigate seismic changes wrought by the budding technology. Since ChatGPT’s launch just over two years ago, several tech giants have launched their own large-language models, many of which have been accused of training their chatbots using copyrighted content, including news reports. While some outlets, including The New York Times, have filed lawsuits over the technology’s alleged scaping of content, others — like Axel Springer, whose news brands include Politico, Business Insider, Bild and Welt — have inked licensing agreements with the developers. window.addEventListener('load', function() { (function(c, id, p, d, w){ var i = d.createElement('iframe'); i.height = '0'; i.width = '0'; i.style = { display: 'none', position: 'absolute', visibility: 'hidden' }; i.src = "https://newsource-embed-prd.ns.cnn.com/articles/cnnvan-stats.html?article_id="+id+"&category="+c+"&publisher="+p+"&url=" + encodeURI(w.location); d.body.appendChild(i); })("Business%2FConsumer", "L19jb21wb25lbnRzL2FydGljbGUvaW5zdGFuY2VzL2NtNHZyM3g0NjAwMG4yY3A5M2pzNjFtdGw%3D", "3244", document, window)})A fight broke out at midfield between the rivals Saturday after Michigan upset Ohio State at Ohio Stadium in Columbus. (FOX Sports) Vice President-elect JD Vance commended his Ohio State Buckeyes after their shocking loss to rival Michigan Saturday. The internet was not so kind in response. Vance posted on X, saying the Buckeyes played like "champions" and that he's "proud of them." "To the OSU seniors on that team: I know it sucks to lose four to Michigan, but for your entire college career you guys have conducted yourselves like champions. I speak for nearly all of us fans when I say: we’re proud of you!" Vance wrote. The Buckeyes blew the game as 21-point favorites, losing to their top rival for the fourth straight time. Michigan's 2024 team is the worst the program has fielded in years, entering the game with a 6-5 record. CLICK HERE FOR MORE SPORTS COVERAGE ON FOXNEWS.COM Davis Warren (16) of the Michigan Wolverines carries the ball against the Ohio State Buckeyes during the fourth quarter at Ohio Stadium Nov. 30, 2024, in Columbus, Ohio. (Jason Mowry/Getty Images) Entering the game, Ohio State was ranked No. 2 with a record of 10-2 and was vying for a spot in the Big 10 championship game and a College Football Playoff berth. Now both of those goals are in question for coach Ryan Day and his team. The Buckeyes were also involved in a brawl with Michigan players after the game. OHIO STATE LOSES TO MICHIGAN FOR FOURTH STRAIGHT YEAR IN HUGE UPSET; PLAYOFF STATUS NOW UP IN THE AIR Vance was the recipient of plenty of shots for his pledged loyalty to the team in response. "Ohio State sucks and so do you!" one user wrote. Another user said Vance's post prompted him to rethink his approval of Vance as Trump's VP pick. "First time I’ve disagreed with JD in a [minute], maybe Trump should have went a different route for the VP role!" the user wrote. Players scrum at midfield after Saturday’s game between the Ohio State Buckeyes and the Michigan Wolverines. (Imagn) Another user questioned Vance praising players who would start a postgame brawl. "'Conducted yourselves like champions' didn’t they just get into a brawl that resulted in Michigan players being pepper sprayed because they were sore losers?" the user wrote. Several law enforcement officers were also involved in breaking up the fight. Videos shared on social media appeared to show players being pepper sprayed, and both Michigan and Ohio State players appeared to be in pain from it. In the immediate aftermath of the fight, Michigan running back Kalel Mullings told FOX Sports in an on-field interview the incident was "bad for the sport." CLICK HERE TO GET THE FOX NEWS APP "It was such a great game. You hate to see stuff like that happen after the game. Bad for the sport, bad for college football. But, at the end of the game, they gotta learn how to lose, man. You can't be fighting and stuff just because you lost a game." Vance previously revealed he had told Trump his loyalty to the Buckeyes could affect Trump's chances of winning the key battleground state of Michigan. "When he first asked me to be a VP, I was like, 'Well, you know, hopefully we don't lose Michigan by like 900 votes, because you're going to regret it. 'Cause it's probably just a thousand p---ed-off Wolverine fans who wouldn't vote for a Buckeye," Vance said during an appearance on OutKick's "The Clay Travis and Buck Sexton Show." "But I think that most Michiganders are going to be able to put sports rivalries aside and put the country first, which is what, of course, all of us believe is the most important thing." The Democratic National Committee attempted to exploit Vance's connection to Ohio State with a campaign strategy in Michigan in early September. The DNC flew a plane over a Michigan football game Sept. 7 with a banner that said, "J.D. Vance [loves] Ohio State [plus] Project 2025." Sen. J.D. Vance, R-Ohio, the Republican vice presidential nominee, introduces Former President Trump, the Republican presidential nominee, during a rally at Herb Brooks National Hockey Center July 27, 2024, in St Cloud, Minn. (Stephen Maturen/Getty Images) The Trump-Vance ticket ended up easily carrying Michigan. Vance also suggested in that interview that Trump and Vance would attend Saturday's game if they won the election. "Well, let's go to the Ohio State-Michigan game, assuming we win, because I bet I can get some pretty sweet tickets as the VP-elect, and we'll be in a celebratory mood," Vance said on OutKick. "And, look, it's, it's going to be a big game this year. I think it's going to determine ultimate seeding in the College Football Playoff. "I mean, now both teams might actually make the playoff. I know Michigan's, you know, sort of people aren't putting them as high this year, but you never know, because it's always a good program. So, we'll see, guys. I'm feeling very good about the Buckeyes. I'm feeling very good about the Bengals." Neither Trump nor Vance attended Saturday's Ohio State-Michigan game. Follow Fox News Digital’s sports coverage on X , and subscribe to the Fox News Sports Huddle newsletter . Jackson Thompson is a sports writer for Fox News Digital. He previously worked for ESPN and Business Insider. Jackson has covered the Super Bowl and NBA Finals, and has interviewed iconic figures Usain Bolt, Rob Gronkowski, Jerry Rice, Troy Aikman, Mike Trout, David Ortiz and Roger Clemens.WEST PALM BEACH, Fla. (AP) — President-elect Donald Trump on Saturday threatened 100% tariffs against a bloc of nine nations if they act to undermine the U.S. dollar. His threat was directed at countries in the so-called BRIC alliance, which consists of Brazil, Russia, India, China, South Africa, Egypt, Ethiopia, Iran and the United Arab Emirates. Turkey, Azerbaijan and Malaysia have applied to become members and several other countries have expressed interest in joining. While the U.S. dollar is by far the most-used currency in global business and has survived past challenges to its preeminence, members of the alliance and other developing nations say they are fed up with America’s dominance of the global financial system . The dollar represents roughly 58% of the world’s foreign exchange reserves, according to the IMF and major commodities like oil are still primarily bought and sold using dollars. The dollar's dominance is threatened, however, with BRICS' growing share of GDP and the alliance's intent to trade in non-dollar currencies — a process known as de-dollarization. Trump, in a Truth Social post, said: “We require a commitment from these Countries that they will neither create a new BRICS Currency, nor back any other Currency to replace the mighty U.S. Dollar or, they will face 100% Tariffs, and should expect to say goodbye to selling into the wonderful U.S. Economy." At a summit of BRIC nations in October, Russian President Vladimir Putin accused the U.S. of “weaponizing” the dollar and described it as a “big mistake.” “It’s not us who refuse to use the dollar,” Putin said at the time. “But if they don’t let us work, what can we do? We are forced to search for alternatives.” Russia has specifically pushed for the creation of a new payment system that would offer an alternative to the global bank messaging network, SWIFT, and allow Moscow to dodge Western sanctions and trade with partners. Trump said there is "no chance" BRIC will replace the U.S. dollar in global trade and any country that tries to make that happen "should wave goodbye to America.” Research shows that the U.S. dollar's role as the primary global reserve currency is not threatened in the near future. An Atlantic Council model that assesses the dollar’s place as the primary global reserve currency states the dollar is “secure in the near and medium term” and continues to dominate other currencies. Trump's latest tariff threat comes after he threatened to slap 25% tariffs on everything imported from Mexico and Canada, and an additional 10% tax on goods from China, as a way to force the countries to do more to halt the flow of illegal immigration and drugs into the U.S. He has since held a call with Mexican President Claudia Sheinbaum, who said Thursday she is confident that a tariff war with the United States can be averted. Canadian Prime Minister Justin Trudeau returned home Saturday after meeting Trump, without assurances the president-elect will back away from threatened tariffs on Canada.DEAR ABBY: Six years ago, my family lost my mother, who was the rock of our family. Two weeks after that, my family started falling apart. My older brother, younger sister and I no longer speak. My brother and I got in a physical confrontation and haven’t spoken since. A year later, I suffered a massive heart attack. I was at death’s door. My doctors said it was a miracle I survived. I’m blessed to be here, but since then, not one family member has reached out. The story of my survival was all over social media and even on a few TV newscasts. My heart function is low, and I had a defibrillator implanted. I have been missing my family more and more, but I’m also afraid my heart will get broken. We have made mistakes, and I know I’m also at fault. I feel awful about what happened, but I’m hurt that no one reached out to my wife or daughter asking if I was OK or if they needed anything. I recently had some contact with my brother’s son, and we have been texting, but I have yet to hear from my brother. My family is growing with grandkids, and I would love to reconnect our families before it’s too late. Is it too late? – Estranged in Pennsylvania DEAR ESTRANGED: Maybe, maybe not. If you haven’t already, write or call your brother and make a formal apology for what happened between you. While you are at it, do the same with the rest of your family members. Tell them you are sorry, that none of you is getting any younger and you would like to be part of the family again. I can’t predict the outcome, but this would be a good start. I wish you luck. With the passage of time, people sometimes gain a better perspective. DEAR ABBY: My sister “Mary Ann” is a hoarder. She refuses all offers of assistance (physically and emotionally) to clear her home of the overwhelming amount of stuff that negatively impacts her life. Our extended family is thrilled that she has finally started to make an effort to sort through some of her “treasures.” Unfortunately, we have now become recipients of birthday and Christmas gifts, some of which are opened, used, dusty and have animal fur on them. We do not want or need these “gifts.” I sense that unloading these items on us gives Mary Ann a feeling of comfort and keeps her from making difficult decisions that will lead to truly changing her thinking related to letting go of her junk. How do we politely (and firmly) express to Mary Ann that we have no desire to receive her hoard, bit by bit, without reversing the progress she has made in attempting to address her disorder? – Unhappy Recipient in Missouri DEAR RECIPIENT: You are not going to “fix” Mary Ann. Be glad she is taking baby steps to help herself. I do not think it would be helpful to “politely express” that you have no desire to receive her hoard, bit by bit. Instead, accept the items and then quietly donate them or give them to someone who might use them. Dear Abby is written by Abigail Van Buren, also known as Jeanne Phillips, and was founded by her mother, Pauline Phillips. Contact Dear Abby at www.DearAbby.com or P.O. Box 69440, Los Angeles, CA 90069.

Vance takes on a more visible transition role, working to boost Trump’s most contentious picksNATO and Ukraine to hold emergency talks after Russian attack with hypersonic missile

Salesforce reports upbeat annual guidance after mixed Q3 resultsAadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO ® and Associated Infrastructure to KAKEN Pharmaceutical for $100M ; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of Directors Aadi to Hold Webcast and Conference Call on December 20 at 8:00 AM EST LOS ANGELES , Dec. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. ( HANGZHOU DAC), a global leader in ADC innovation. Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging HANGZHOU DAC's CPT113 linker payload technology targeting each of Protein Tyrosine Kinase 7 (PTK7), Mucin-16 (MUC16) and Seizure Related 6 Homolog (SEZ6). Aadi will pay aggregate upfront payments of $44 million for in-licensing such ADC programs. Additionally, Aadi is obligated to pay cumulative development milestone payments of up to $265 million , cumulative commercial milestone payments of up to $540 million and single-digit royalties of sales. To support this transaction, Aadi entered into a subscription agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $100 million , before deducting placement agent fees and other offering expenses. The Company is selling an aggregate of 21,592,000 shares of its common stock ("Common Stock") at a price of $2.40 per share, representing a premium of approximately 3.4% to the closing price on December 19, 2024 on Nasdaq, and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 20,076,500 shares of Common Stock at a purchase price of $2.3999 per Pre-Funded Warrant share. The syndicate was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners. The PIPE financing is expected to close in the first half of 2025, subject to stockholder vote and satisfaction of customary closing conditions. "I'm thrilled to announce our partnership with WuXi Biologics and HANGZHOU DAC to bring forward this thoughtfully selected ADC portfolio. We were deliberate in identifying broadly expressed tumor targets where first-generation ADCs have already shown proof of concept. With our next wave ADC portfolio, we aim to build upon these earlier therapies to deliver improved outcomes for people living with cancer," said David Lennon , PhD, President and CEO of Aadi Bioscience. "The financing underscores the confidence our investors have in both the potential of this portfolio and the strength of Aadi's management team." About the ADC Portfolio Each of the three ADC assets utilizes HANGZHOU DAC's CPT113 ADC platform, which consists of a highly stable yet cleavable linker that delivers a Topoisomerase I (TOPO1) inhibitor payload. The CPT113 platform's linker stability and novel payload has the potential to be highly competitive among the next generation ADC platforms. To effectively leverage the CPT113 platform, Aadi selected tumor targets that are upregulated in high-potential cancer indications and where clinical efficacy has been demonstrated by first-generation ADCs. These assets were discovered through the collaborative efforts of WuXi Biologics and HANGZHOU DAC, utilizing the innovative antibody discovery platform provided by WuXi Biologics and advanced linker-payload technology provided by HANGZHOU DAC. "Leveraging our advanced antibody discovery service, we're glad to enable Aadi to accelerate the discovery of precision therapies targeting some of the most challenging cancers," said Dr. Chris Chen , CEO of WuXi Biologics. "This collaboration underscores our wide recognition as an industry leader in discovery service solutions, and further validates our ability to provide integrated discovery technology platforms for global partners to develop next-generation modalities. We look forward to partnering with Aadi and HANGZHOU DAC to expeditiously move these assets forward into clinical development and benefit patients worldwide." " HANGZHOU DAC's CPT-ADC platform is designed to enable next wave ADC capabilities that surpass first-generation technologies, including two programs already in clinical development in China ," said Dr. Robert Y. Zhao , President and CEO of HANGZHOU DAC Biotechnology. "As a global leader in ADC innovation, we are excited to partner with Aadi and WuXi Biologics to deliver this promising portfolio to patients." Aadi to Sell FYARRO for $100 Million , Cumulative Capital Expected to Fund Operations into Late 2028 In a separate agreement, KAKEN Pharmaceutical Co., Ltd., an R&D driven pharmaceutical company in Japan , has entered into a stock purchase agreement under which KAKEN will acquire Aadi Subsidiary, Inc. and all of its assets, including FYARRO ® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) and associated infrastructure, including the majority of Aadi employees who support the FYARRO ® business. FYARRO is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), with cumulative revenue of $25.2 million reported over the prior four quarters ended September 30, 2024 . Per the terms of the agreement, Kaken will pay Aadi $100 million in cash at closing, subject to certain adjustments. The transaction is expected to close in the first half of 2025, subject to Aadi stockholder approval and certain closing conditions. Upon the closing of this transaction, KAKEN will also acquire the rights to the Aadi name and trademark. "We are enormously proud of the impact FYARRO has had for people with PEComa, and Kaken's capabilities, coupled with the proven track record of the Aadi team, ensures physicians and patients will continue to have access to this critical treatment," said Lennon. The net proceeds from the PIPE financing and the sale of FYARRO, together with the Company's existing cash, cash equivalents and marketable securities are expected to fund operations into late-2028, including anticipated clinical data readouts for the ADC portfolio. Baiteng Zhao Appointed to the Board of Directors, Brings Significant ADC Expertise Baiteng Zhao, PhD, joins Aadi's board of directors. Zhao co-founded ProfoundBio, a clinical stage next-gen ADC developer, in 2018 and served as the Chairman and CEO of the company until it was acquired by Genmab for $1.8 billion in May 2024 . Prior to ProfoundBio, Dr. Zhao worked at Seagen (now part of Pfizer) for more than eight years and was responsible for the modeling and simulation strategies for the development pipeline and supported preclinical and clinical development of ADC drug candidates. "We are delighted to welcome Baiteng to our Board. His deep expertise and successful track record in ADC development will be instrumental as we tenaciously move this exciting portfolio forward," said Caley Castelein , MD, Chair of the Board of Directors of Aadi Bioscience. "I am thrilled to join the Board at this pivotal moment for Aadi," said Baiteng Zhao, PhD, Board of Directors of Aadi Bioscience and co-founder of ProfoundBio. "PTK7, MUC16 and SEZ6 represent highly promising targets that are commonly overexpressed in cancers with significant unmet therapeutic needs. Coupled with an advanced linker-payload platform that has the potential to enable next-gen ADCs, I believe Aadi is uniquely positioned to make a meaningful impact on patient outcomes. I look forward to collaborating with the leadership team and fellow Board directors to advance these innovative programs and drive transformative progress for patients." Advisors Leerink Partners is serving as financial advisor to Aadi on the sale of FYARRO and the licensing of the ADC portfolio. Jefferies LLC is acting as exclusive placement agent for the PIPE financing. Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal counsel to Aadi. McDermott Will & Emery LLP is serving as legal counsel to Kaken. Cooley LLP is serving as legal counsel to Jefferies LLC. Nomura Securities Co., Ltd. is serving as financial advisor to KAKEN. Conference Call Information The Aadi management team is hosting a conference call and webcast tomorrow, Friday, December 20 th at 8:00 AM EST ( 5:00 AM PST ) to discuss these updates. Participants may access a live webcast of the call and the associated slide presentation on these data through the "Investors & News" page of the Aadi Bioscience website at aadibio.com . To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. Additional Information for Stockholders This communication relates to the proposed sale of FYARRO and the proposed PIPE financing and may be deemed to be solicitation material in respect of such transactions. In connection with these proposed transactions, Aadi will file a Proxy Statement with the SEC. This communication is not a substitute for the Proxy Statement or any other documents that Aadi may file with the SEC or send to Aadi stockholders in connection with the proposed transactions. Before making any voting decision, investors and securityholders are urged to read the Proxy Statement and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transactions as they become available because they will contain important information about the proposed transactions and related matters. Stockholders may obtain a copy of the Proxy Statement and other documents the Company files with the SEC (when they are available) through the website maintained by the SEC at www.sec.gov , as well as on the Investor and News section of Aadi's website at www.aadibio.com . Certain stockholders of Aadi holding approximately 36% of Aadi's outstanding shares, as of the date hereof, including members of its board of directors and related entities, have entered into voting and support agreements in favor of KAKEN Pharmaceutical and Aadi, pursuant to which such stockholders have agreed to vote in favor of the stock purchase transaction with KAKEN Pharmaceutical and the other transactions described above. Participants in the Solicitation Aadi and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Aadi in connection with the proposed transactions. Information about Aadi's directors and executive officers is set forth in Aadi's definitive proxy statement filed with the SEC on April 26, 2024 , and in subsequent filings made by Aadi with the SEC. Other information regarding the interests of such individuals, as well as information regarding Aadi's directors and executive officers and other persons who may be deemed participants in the proposed transactions, will be set forth in the Proxy Statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of these documents as described in the preceding paragraph. No Offer or Solicitation This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor a solicitation of any vote or approval with respect to the proposed transactions or otherwise, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offer and sale of securities of Aadi described above are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended, and may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. Concurrently with the execution of the subscription agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file, following the closing of the PIPE financing, a registration statement with the SEC registering the resale of the shares of Common Stock and the shares of Common Stock underlying the Pre-Funded Warrants sold in the PIPE financing. About Aadi Bioscience Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on LinkedIn. Forward-Looking Statements This press release contains certain forward-looking statements regarding the business of Aadi Bioscience that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to: the timing and completion of the proposed sale of FYARRO to Kaken Pharmaceuticals and the anticipated timing of the closing of the transaction; expectations regarding the timing, closing and completion of the PIPE financing; Aadi's expected cash position at the closing and cash runway of the company following the sale of FYARRO and PIPE financing; the future operations of Aadi; the development and potential benefits of any of Aadi's product candidates, including the preclinical ADC assets proposed to be licensed from WuXi; anticipated preclinical and clinical development activities and related timelines, including the expected timing for announcement of data and other preclinical and clinical results and potential submission of IND filings for one or more product candidates; and other statements that are not historical fact. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks associated with (i) the risk that the conditions to the closing of the proposed sale of FYARRO or the PIPE financing are not satisfied, including the failure to timely obtain stockholder approval for the transactions, if at all; (ii) uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of Kaken and Aadi to consummate the proposed sale of FYARRO; (iii) risks related to Aadi's ability to manage its operating expenses and its expenses associated with the proposed transactions pending the closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transactions; (v) unexpected costs, charges or expenses resulting from the transactions; (vii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed sale of FYARRO or the proposed PIPE financing; (vii) the uncertainties associated with Aadi's product candidates, as well as risks associated with the preclinical and clinical development and regulatory approval of product candidates, including potential delays in the completion of preclinical studies and clinical trials; (viii) risks related to the inability of Aadi to obtain sufficient additional capital to continue to advance these product candidates; (ix) uncertainties in obtaining successful preclinical and clinical results for product candidates and unexpected costs that may result therefrom; (x) risks related to the failure to realize any value from product candidates being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xi) risks associated with the possible failure to realize certain anticipated benefits of the proposed sale of FYARRO or the proposed PIPE financing, including with respect to future financial and operating results. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 , including under the caption "Item 1A. Risk Factors," and in Aadi's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Aadi's reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at www.sec.gov . All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: IR@aadibio.com View original content to download multimedia: https://www.prnewswire.com/news-releases/aadi-bioscience-transforms-with-in-licensing-of-novel-adc-portfolio-100-million-sale-of-fyarro-and-100-million-pipe-financing-302336743.html SOURCE Aadi Bioscience

Stock markets to end 2024 with positive returns despite roller coaster ride

Jalon Moore led No. 12 Oklahoma with 22 points in an 89-67 home win against pesky Prairie View A&M in Norman on Sunday. Jeremiah Fears scored 19 points and Duke Miles added 17 for the Sooners, who are 13-0 for the fourth time in program history and the first time since the 1987-88 season. Tanahj Pettway led PVAMU with 22 points while Marcel Bryant added 14. Braelon Bush and Jordan Tillmon each chipped in 11 points for PVAMU (1-13) which played without leading scorer Nick Anderson (18.9 points per game). The Sooners finally pulled away from the determined Panthers with 5:20 left on a 10-3 run that started when Sam Goodwin tipped in a rebound and was capped by a Glenn Taylor Jr. rebound for an 80-63 lead. A Kobe Elvis 3-pointer capped a game-closing 9-0 Sooners run. Pettway connected on a 3-pointer from the wing that gave the Panthers a 5-2 lead. PVAMU hung tight on a Bryant jumper that tied the game at 7. Even though they were short-handed, the Panthers' largest first-half deficit was only 11. A Pettway layup and his steal in the full-court press that led to Bryant's turnaround jumper in the lane as the Panthers closed within 34-30. PVAMU's rally prompted an Oklahoma timeout after which Miles drilled a 3-pointer to kick off a half-closing 9-2 spurt for a 43-32 halftime lead. Braelon Bush's 3-pointer pulled the Panthers within 58-50 with 11:17 left in the game. It was the Panthers' 12th straight nonconference road game. PVAMU returns to its home court Saturday against Grambling. Oklahoma kicks off its first season in the SEC at No. 5 Alabama on Saturday. --Field Level MediaFranklin Covey to Report First Quarter Fiscal 2025 Results

Cetera Strengthens Executive Leadership to Propel Strategic Growth and InnovationDemocrats stick with Schumer as leader. Their strategy for countering Trump is far less certain

Wildwood Wildlife Shelter operator Pam Turner wasn’t going anywhere on Boxing Day despite her fears the Grampians bushfire could head her way – she had a lounge room with 20 joeys in it to look after. She and the rescued roos sheltered inside her Victoria Valley house as sprinklers doused the roof and sheds outside. “I was extremely anxious. I was preparing myself for a giant fireball to come over the mountains,” Turner said. “I chose to stay for the very reason that I had a cottage full of joeys. How could I leave them locked in the cottage?” The forecast 70-kilometre northeasterly winds that threatened to blow the fire towards Wildwood failed to eventuate, and rainfall on Saturday brought some relief to the shelter. But Turner remains worried about what may be yet to come. Three homes in the town of Moyston and 11 outbuildings in the surrounding area have been reported as destroyed by the Grampians blaze so far, and animal rescuers are waiting for permission to enter the Grampians National Park to assess wildlife losses. Pam Turner caring for one of the joeys she kept safe during the Grampians bushfires. The blaze, whose perimeter stretches more than 380 kilometres, has scorched more than 75,000 hectares and is expected to burn into the new year due to dry conditions and difficult, mountainous terrain. Authorities have reported stock losses, as well as beehive, fencing, pasture and hay losses from the fire, which began early last week. Turner was part of the wildlife rescue effort following the Mount Lubra fire, which burnt half the Grampians in 2006. She said the loss of life had left her traumatised. “For months afterwards we were finding injured kangaroos, burnt on the pads of their feet. They were starving because there was no food,” she said. “At this stage, we don’t know what to expect – [the current fire] will certainly be ongoing for weeks and weeks.” An officer from the Environment Department was deployed to assess wildlife losses outside the fire zone this week and was expected to determine whether a triage centre was required to treat injured animals in coming days. Emergency services described the Boxing Day conditions as some of the worst they had seen since the Black Summer fires of 2019-20. Credit: Justin McManus Wildlife Victoria has experienced an increase in calls about heat-stressed animals since summer began and expected calls for burns and dehydration to spike as people returned to the Grampians. Residents of Halls Gap were given permission to return to their homes on Friday, but the park remained closed to tourists. McKenzie Creek resident Brendan Stemp was on alert for changes to weather conditions that could blow embers towards his cattery and neighbouring farmland. Stemp said the more than 30 cats at his property had been kept comfortable during the worst fire conditions, but he was expecting significant damage to wildlife inside the park. “Because it’s such a huge area, there’s millions of animals in there, and all these other critters and insects that the fire’s going to take a huge toll on,” he said. Stemp said the other concern was wildlife being pushed out into grazing land and having to compete with sheep and cattle for food. “Often wildlife come off second best when that happens.” Three homes and 11 outbuildings have been lost in the Grampians fire so far. Credit: Justin McManus Cooler conditions in the Wimmera at the weekend are forecast to be replaced by warmer weather next week. The Bureau of Meteorology has predicted temperatures in the low 30s on Monday and up to 35 degrees on Tuesday. Emergency Management Commissioner Rick Nugent said the next week would provide favourable conditions for firefighters. “Weather over the next week looks relatively stable. This will allow us time to stabilise the fires and continue back-burning operations, and look to support the community further,” Nugent said. In addition to state and federal support for local government areas affected by the Grampians fire, personal hardship payments are now available. One-off payments of $680 for adults and $340 for children up to $2380 per affected family are being provided to help cover essentials. Loading Forest Fire Management Victoria spokesman Chris Hardman said it was thanks to firefighters that the fire situation had not been worse in recent days. “Without their hard work, we would have had much bigger fires causing much bigger damage,” Hardman said. “On behalf of all Victorians I would like to thank them because what they did on Boxing Day in extreme fire danger saved a lot more anguish and pain that Victorians now don’t have to suffer.” The Morning Edition newsletter is our guide to the day’s most important and interesting stories, analysis and insights. Sign up here . Save Log in , register or subscribe to save articles for later. License this article Bushfires Animals Wildlife Fire Grampians Alex Crowe is an education reporter. She joined The Age as a breaking news reporter in 2023. Connect via Twitter , Facebook or email . Most Viewed in National LoadingCARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.Jimmy Carter, the 39th US president, has died at 100

Times Square New Year's Eve Ball Drop—When and where to tune in; your ultimate viewing guideInventus Mining Corp. ( CVE:IVS – Get Free Report )’s stock price was down 21.1% during mid-day trading on Saturday . The stock traded as low as C$0.08 and last traded at C$0.08. Approximately 118,000 shares changed hands during mid-day trading, an increase of 26% from the average daily volume of 93,681 shares. The stock had previously closed at C$0.10. Inventus Mining Trading Down 21.1 % The stock has a 50 day moving average of C$0.06 and a 200 day moving average of C$0.05. The company has a debt-to-equity ratio of 41.50, a current ratio of 1.44 and a quick ratio of 0.07. The firm has a market cap of C$12.60 million, a P/E ratio of -7.00 and a beta of 0.83. Insider Transactions at Inventus Mining In other Inventus Mining news, Director Glen Alexander Milne bought 577,000 shares of Inventus Mining stock in a transaction that occurred on Tuesday, November 19th. The shares were bought at an average price of C$0.06 per share, with a total value of C$31,735.00. In the last three months, insiders bought 1,952,000 shares of company stock worth $99,235. 31.70% of the stock is currently owned by corporate insiders. Inventus Mining Company Profile Inventus Mining Corp. engages in the acquisition, exploration, and development of mineral properties in Canada. The company explores for gold and base metals. It holds 100% interests in the Pardo Paleoplacer gold project covering an area of 3.8 square kilometers block of mineral leases and 180 square kilometers of mineral claims; and Sudbury 2.0 project totaling an area of 240 square kilometers of mineral claims located in Sudbury Mining Division, Ontario. See Also Receive News & Ratings for Inventus Mining Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventus Mining and related companies with MarketBeat.com's FREE daily email newsletter .SoftwareONE Holding AG (OTCMKTS:SWONF) Sees Large Growth in Short Interest

Jimmy Carter, a peanut farmer and little-known Georgia governor who became the 39th president of the United States, promising “honest and decent” government to Watergate-weary Americans, and later returned to the world stage as an influential human rights advocate and Nobel Peace Prize winner, has died. He was 100. When his turbulent presidency ended after a stinging reelection loss in 1980, Carter retreated to Plains, his political career over. Over the four decades that followed, though, he forged a legacy of public service, building homes for the needy, monitoring elections around the globe and emerging as a fearless and sometimes controversial critic of governments that mistreated their citizens. He lived longer than any U.S. president in history and was still regularly teaching Bible classes at his hometown Maranatha Baptist Church well into his 90s. During his post-presidency, he also wrote more than 30 books, including fiction, poetry, deeply personal reflections on his faith, and commentaries on Middle East strife. Though slowed by battles with brain and liver cancer and a series of falls and hip replacement in recent years, he returned again and again to his charity work and continued to offer occasional political commentary, including in support of mail-in voting ahead of the 2020 presidential election. Carter was in his first term as Georgia governor when he launched his campaign to unseat President Gerald Ford in the 1976 election. At the time, the nation was still shaken by President Richard Nixon’s resignation in the Watergate scandal and by the messy end of the Vietnam War. As a moderate Southern Democrat, a standard-bearer of what was then regarded as a more racially tolerant “new South,” Carter promised a government “as good and honest and decent and competent and compassionate and as filled with love as are the American people.” But some of the traits that had helped get Carter elected — his willingness to take on the Washington establishment and his preference for practicality over ideology — didn’t serve him as well in the White House. He showed a deep understanding of policy, and a refreshing modesty and disregard for the ceremonial trappings of the office, but he was unable to make the legislative deals expected of a president. Even though his Democratic Party had a majority in Congress throughout his presidency, he was impatient with the legislative give-and-take and struggled to mobilize party leaders behind his policy initiatives. His presidency also was buffeted by domestic crises — rampant inflation and high unemployment, as well as interminable lines at gas stations triggered by a decline in the global oil supply exacerbated by Iran’s Islamic Revolution. “Looking back, I am struck by how many unpopular objectives we pursued,” Carter acknowledged in his 2010 book, “White House Diary.” “I was sometimes accused of ‘micromanaging’ the affairs of government and being excessively autocratic,” he continued, “and I must admit that my critics probably had a valid point.” Carter’s signature achievements as president were primarily on the international front, and included personally brokering the Camp David peace accords between Egypt and Israel, which have endured for more than 40 years. But it was another international crisis — the storming of the U.S. Embassy in Tehran by Iranian revolutionaries and the government’s inability to win the release of 52 Americans taken hostage — that would cast a long shadow on his presidency and his bid for reelection. Carter authorized a secret military mission to rescue the hostages in April 1980, but it was aborted at the desert staging area; during the withdrawal, eight servicemen were killed when a helicopter crashed into a transport aircraft. The hostages were held for 444 days, a period that spanned Carter’s final 15 months in the White House. They were finally freed the day his successor, Ronald Reagan, took the oath of office. Near the end of Carter’s presidency, one poll put his job approval rating at 21% — lower than Nixon’s when he resigned in disgrace and among the lowest of any White House occupant since World War II. In a rarity for an incumbent president, Carter faced a formidable primary challenge in 1980 from Sen. Edward M. Kennedy, a favorite of the Democratic Party’s liberal wing. Although Carter prevailed, his nomination was in doubt until the party’s August convention. The enmity between Carter and Kennedy, two of the most important Democratic political figures of their generation, continued throughout their lives. In Kennedy’s memoir, published shortly after his death in 2009, he called Carter petty and guilty of “a failure to listen.” While promoting the publication of “White House Diary,” Carter said Kennedy had “deliberately” blocked Carter’s comprehensive healthcare proposals in the late 1970s in hopes of defeating the president in the primary. In the 1980 general election, Carter faced Reagan, then 69, who campaigned on a promise to increase military spending and rescue the economy by cutting taxes and decreasing regulation. Carter lost in a 51% to 41% thumping — he won just six states and the District of Columbia — that devastated the man known for his toothy smile and sent him back to his hometown, an ex-president at 56. A year later, he and Rosalynn founded the Carter Center, which pressed for peaceful solutions to world conflicts, promoted human rights and worked to eradicate disease in the poorest nations. The center, based in Atlanta, launched a new phase of Carter’s public life, one that would move the same historians who called Carter a weak president to label him one of America’s greatest former leaders. His post-presidential years were both “historic and polarizing,” as Princeton University historian Julian E. Zelizer put it in a 2010 biography of Carter. Zelizer said Carter “refused to be constrained politically when pursuing his international agenda” as an ex-president, and became “an enormously powerful figure on the international stage.” When Carter appeared on “The Colbert Report” in 2014, host Stephen Colbert asked him, “You invented the idea of the post-presidency. What inspired you to do that?” “I didn’t have anything else to do,” Carter replied. He traveled widely to mediate conflicts and monitor elections around the world, joined Habitat for Humanity to promote “sweat equity” for low-income homeownership, and became a blunt critic of human rights abuses. He angered conservatives and some liberals by advocating negotiations with autocrats — and his criticism of Israeli leaders and support for Palestinian self-determination angered many Jews. A prolific author, Carter covered a range of topics, including the Middle East crisis and the virtues of aging and religion. He penned a memoir on growing up in the rural South as well as a book of poems, and he was the first president to write a novel — “The Hornet’s Nest,” about the South during the Revolutionary War. He won three Grammy Awards as well for best spoken-word album, most recently in 2019 for “Faith: A Journey For All.” As with many former presidents, Carter’s popularity rose in the years after he left office. He was awarded the Nobel Peace Prize in 2002 for “decades of untiring effort to find peaceful solutions to international conflicts” and to advance democracy and human rights. By then, two-thirds of Americans said they approved of his presidency. “Jimmy Carter may never be rated a great president,” wrote Charles O. Jones, a University of Wisconsin political scientist, in his chronicle of the Carter presidency. “Yet it will be difficult in the long run to sustain censure of a president motivated to do what is right.” :::: The journey for James Earl Carter Jr. began on Oct. 1, 1924, in the tiny Sumter County, Georgia, town of Plains, home to fewer than 600 people in 2020. He was the first president born in a hospital, but he lived in a house without electricity or indoor plumbing until he was a teenager. His ancestors had been in Georgia for more than two centuries, and he was the fifth generation to own and farm the same land. His father, James Earl Carter Sr., known as Mr. Earl, was a strict disciplinarian and a conservative businessman of some means. His mother, known as Miss Lillian, had more liberal views — she was known for her charity work and for taking in transients and treating Black residents with kindness. (At the age of 70, she joined the Peace Corps, working in India.) Inspired by an uncle who was in the Navy, Carter decided as a first-grader that he wanted to go to the Naval Academy in Annapolis, Md. He became the first member of his family to finish high school, then attended Georgia Tech before heading for the academy, where he studied engineering and graduated in 1946, 59th in a class of 820. Before his last year in Annapolis, while home for the summer, he met Eleanor Rosalynn Smith, a friend of his sister Ruth’s. He and a friend invited the two young women to the movies, and when he returned home that night, he told his mother he had met “the girl I want to marry.” He proposed that Christmas, but Rosalynn declined because she felt she was too young (she was 18 and a sophomore in college). Several weeks later, while she was visiting Carter at the academy, he asked again. This time she said yes. Carter applied to America’s new nuclear-powered submarine program under the command of the icy and demanding Capt. (later Adm.) Hyman Rickover. During Carter’s interview, Rickover asked whether he had done his best at Annapolis. “I started to say, ‘Yes, sir,’ but ... I recalled several of the many times at the Academy when I could have learned more about our allies, our enemies, weapons, strategy and so forth,” Carter wrote in his autobiography. “... I finally gulped and said, ‘No, sir, I didn’t always do my best.’” To which Rickover replied: “Why not?” Carter got the job, and would later make “Why not the best?” his campaign slogan. The Carters had three sons, who all go by nicknames — John William “Jack,” James Earl “Chip” and Donnel Jeffrey “Jeff.” Carter and Rosalynn had wanted to have more children, but an obstetrician said that surgery Rosalynn had to remove a tumor on her uterus would make that impossible. Fifteen years after Jeffrey was born, the Carters had a daughter, Amy, who “made us young again,” Carter would later write. While in the Navy, Carter took graduate courses in nuclear physics and served as a submariner on the USS Pomfret. But his military career was cut short when his father died, and he moved back to Georgia in 1953 to help run the family business, which was in disarray. In his first year back on the farm, Carter turned a profit of less than $200, the equivalent of about $2,200 today. But with Rosalynn’s help, he expanded the business. In addition to farming 3,100 acres, the family soon operated a seed and fertilizer business, warehouses, a peanut-shelling plant and a cotton gin. By the time he began his campaign for the White House 20 years later, Carter had a net worth of about $800,000, and the revenue from his enterprises was more than $2 million a year. Carter entered electoral politics in 1962, and asked voters to call him “Jimmy.” He ran for a seat in the Georgia Senate against an incumbent backed by a local political boss who stuffed the ballot box. Trailing by 139 votes after the primary, Carter waged a furious legal battle, which he described years later in his book “Turning Point.” Carter got a recount, the primary result was reversed, and he went on to win the general election. The victory was a defining moment for Carter, the outsider committed to fairness and honesty who had successfully battled establishment politicians corrupted by their ties to special interests. In two terms in the Georgia Senate, Carter established a legislative record that was socially progressive and fiscally conservative. He first ran for governor in 1966, but finished third in the primary. Over the next four years, he made 1,800 speeches and shook hands with an estimated 600,000 people — a style of campaigning that paid off in the 1970 gubernatorial election and later in his bid for the White House. In his inaugural address as governor in 1971, Carter made national news by declaring that “the time for racial discrimination is over.” He had a portrait of the Rev. Martin Luther King Jr. hung in a hall at the Capitol in Atlanta. But when Carter launched his official campaign for the White House in December 1974, he was still so little-known outside Georgia that a celebrity panel on the TV show “What’s My Line?” couldn’t identify him. In the beginning, many scoffed at the temerity of a peanut farmer and one-term governor running for the highest office in the land. After Carter met with House Speaker Thomas P. “Tip” O’Neill Jr., the speaker was asked whom he had been talking to. “Some fellow named Jimmy Carter from Georgia. Says he’s running for president,” O’Neill replied. In a meeting with editors of the Los Angeles Times in 1975, Carter said he planned to gain the presidency by building a network of supporters and by giving his candidacy an early boost by winning the Iowa caucuses. Until then, Iowa had been a bit player in the nominating process, mostly ignored by strategists. But Carter’s victory there vaulted him to front-runner status — and Iowa into a major role in presidential nominations. His emergence from the pack of Democratic hopefuls was helped by the release of his well-reviewed autobiography “Why Not the Best?” in which he described his upbringing on the farm and his traditional moral values. On the campaign trail, Carter came across as refreshingly candid and even innocent — an antidote to the atmosphere of scandal that had eroded confidence in public officials since the events leading to Nixon’s resignation on Aug. 9, 1974. A Baptist Sunday school teacher, Carter was among the first presidential candidates to embrace the label of born-again Christian. That was underscored when, in an interview with Playboy magazine, he made headlines by admitting, “I’ve looked on many women with lust. I’ve committed adultery in my heart many times. God knows I will do this and forgives me.” Carter had emerged from the Democratic National Convention in July with a wide lead over Ford, Nixon’s vice president and successor, but by the time of the Playboy interview in September, his numbers were tumbling. By election day, the contest was a dead heat. Carter, running on a ticket with Walter F. Mondale for his vice president, eked out a victory with one of the narrower margins in U.S. presidential history, winning 50.1% to 48% of the popular vote and 297 electoral votes, 27 more than needed. Many of Carter’s supporters hoped he would usher in a new era of liberal policies. But he saw his role as more of a problem-solver than a politician, and as an outsider who promised to shake things up in Washington, he often acted unilaterally. A few weeks into his term, Carter announced that he was cutting off federal funding to 18 water projects around the country to save money and protect the environment. Lawmakers, surprised by the assault on their pet projects, were livid. He ultimately backed down on some of the cuts. But his relationship with Congress never fully healed. Members often complained that they couldn’t get in to see him, and that when they did he was in a rush to show them the door. His relationship with the media, as he acknowledged later in life, was similarly fraught. Carter’s image as a reformer also took a hit early in his presidency after he appointed Bert Lance, a longtime confidant, to head the Office of Management and Budget. Within months of the appointment, questions were raised about Lance’s personal financial affairs as a Georgia banker. Adamant that Lance had done nothing wrong, Carter dug in his heels and publicly told his friend, “Bert, I’m proud of you.” Still, Lance resigned under pressure, and although he was later acquitted of criminal charges, the damage to Carter had been done. As Mondale later put it: “It made people realize that we were no different than anybody else.” When Carter did score legislative victories, the cost was high. In 1978, he pushed the Senate to ratify the Panama Canal treaties to eventually hand control of the canal over to Panama. But conservatives criticized the move as a diminution of U.S. strength, and even the Democratic National Committee declined to endorse it. Carter’s most significant foreign policy accomplishment was the 1978 Camp David agreement, a peace pact between Israel and Egypt. But he followed that with several unpopular moves, including his decree that the United States would not participate in the 1980 Summer Olympics in Moscow, as a protest against the Soviet Union’s invasion of Afghanistan. It was the only time in Olympic history that the United States had boycotted an Olympics; the Soviets responded by boycotting the 1984 Summer Games in Los Angeles. Carter had taken a series of largely symbolic steps to dispel the imperial image of the presidency. After he took the oath of office on a wintry day, he and the new first lady emerged from their motorcade and walked part of the way from the Capitol to the White House. He ended chauffeur-driven cars for top staff members, sold the presidential yacht, went to the White House mess hall for lunch with the staff and conducted town meetings around the country. He suspended the playing of “Hail to the Chief” whenever he arrived at an event, though he later allowed the practice to resume. On the domestic front, he was saddled with a country in crisis. Inflation galloped at rates up to 14%, and global gasoline shortages closed service stations and created high prices and long lines. Interest rates for home mortgages soared above 14%. In his first televised fireside chat, he wore a cardigan sweater and encouraged Americans to conserve energy during the winter by keeping their thermostats at 65 degrees in the daytime and 55 degrees at night. He also proposed a string of legislative initiatives to deal with the crisis, but many were blocked by Congress. In what would become a seminal moment in his presidency, Carter addressed the nation — and a television audience of more than 60 million — on a Sunday evening in 1979, saying the country had been seized by a “crisis of confidence ... that strikes at the very heart and soul and spirit of our national will.” He outlined a series of proposals to develop new sources of energy. The address, widely known as the “malaise speech” even though Carter never used that word, was generally well-received at the time, though some bristled at the implication that Americans were to blame for the country’s problems. Any positive glow disappeared two days later, when Carter fired five of his top officials, including the Energy, Treasury and Transportation secretaries and his attorney general. The value of the dollar sank and the stock market tumbled. Sensing that Carter was politically vulnerable, Kennedy moved to present himself as an alternative for the 1980 Democratic nomination, publicly criticizing the president’s agenda. But Kennedy damaged his own candidacy in a prime-time interview with CBS’ Roger Mudd: Asked why he was running for president, Kennedy fumbled his answer, and critics cited it as evidence that the senator didn’t want the job so much as he felt obligated to seek it. A few months after the malaise speech, in late 1979, revolutionaries loyal to Iran’s spiritual leader, the Ayatollah Ruhollah Khomeini, seized the U.S. Embassy in Tehran, taking 52 Americans hostage. Weeks stretched into months, with Iran refusing all efforts to negotiate a hostage release. In April 1980, Carter approved Operation Eagle Claw, a secret Delta Force rescue mission. But it ended in disaster — mechanical trouble sidelined three helicopters and, after the mission was aborted, one of the remaining helicopters collided with a transport plane on the ground, killing eight soldiers. Secretary of State Cyrus R. Vance resigned before the mission, believing the plan too risky. Negotiations to free the hostages resumed, and Carter desperately tried to win their release before the November election. But the Iranians prolonged the talks and the hostages weren’t released until Jan. 20, 1981, moments after Carter watched Reagan being sworn in. The journey home for Carter was painful. Of those who voted for Reagan in 1980, nearly 1 in 4 said they were primarily motivated by their dissatisfaction with Carter. :::: Carter faced “an altogether new, unwanted and potentially empty life,” as he later put it. He sold the family farm-supply business, which had been placed in a blind trust during his presidency and was by then deeply in debt. Then, as Rosalynn later recalled, Carter awoke one night with an idea to build not just a presidential library but a place to resolve global conflicts. Together, they founded the nonprofit, nonpartisan Carter Center. His skill as a mediator made Carter a ready choice for future presidents seeking envoys to navigate crises. Republican President George H.W. Bush sent him on peace missions to Ethiopia and Sudan, and President Bill Clinton, a fellow Democrat, dispatched him to North Korea, Haiti and what then was Yugoslavia. Carter described his relationship with President Barack Obama as chilly, however, in part because he had openly criticized the administration’s policies toward Israel. He felt Obama did not strongly enough support a separate Palestinian state. “Every president has been a very powerful factor here in advocating this two-state solution,” Carter told the New York Times in 2012. “That is now not apparent.” As an election observer, he called them as he saw them. After monitoring presidential voting in Panama in 1989, he declared that Manuel Noriega had rigged the election. He also began building houses worldwide for Habitat for Humanity, and he wrote prodigiously. The Nobel committee awarded Carter the Peace Prize in 2002, more than two decades after he left the White House, praising him for standing by “the principles that conflicts must as far as possible be resolved through mediation and international cooperation.” During his 70s, 80s and even into his 90s, the former president showed an energy that never failed to impress those around him. In his 1998 book “The Virtues of Aging,” he urged retirees to remain active and engaged, and he followed his own advice, continuing to jog, play tennis and go fly-fishing well into his 80s. When his “White House Diary” was published in 2010, he embarked on a nationwide book tour at 85, as he did in 2015 with the publication of “A Full Life: Reflections at 90.” When he told America he had cancer that had spread to his liver and brain, it was vintage Carter. Wearing a coat and tie and a pair of blue jeans, he stared into the television cameras and was unflinchingly blunt about his prognosis. “Hope for the best; accept what comes,” he said. “I think I have been as blessed as any human being in the world.” Former Times staff writers Jack Nelson, Robert Shogan and Johanna Neuman contributed to this report. ©2024 Los Angeles Times. Visit at latimes.com . Distributed by Tribune Content Agency, LLC.Apple urged to remove new AI feature after falsely summarizing news reports

Seazen Group Limited (OTCMKTS:SZENF) Short Interest Update

Jimmy Carter , the 39th President of the United States, has died at 100. The longest-living president in U.S. history died almost two years after entering hospice care in his Georgia home in lieu of continued medical intervention for his various health issues. Carter was a one-term but popular president, holding office from 1977-1981, and was unseated by Ronald Reagan. The former Commander in Chief’s nonprofit organization announced he was entering hospice care in February 2023. “After a series of short hospital stays, former U.S. President Jimmy Carter decided to spend his remaining time at home with his family and receive hospice care instead of additional medical intervention,” the February 18 Twitter announcement read. “He has the full support of his family and his medical team. The Carter family asks for privacy during this time and is grateful for the concern shown by his many admirers.” Carter had undergone multiple hospital stints in recent years for various health issues, such as melanoma and several falls. On August 2, 2015, Carter underwent surgery to remove a small cancerous mass in his liver, and he recovered easily. However, the procedure revealed further health complications. On August 11, 2015, it was announced that the cancer had spread to other parts of Carter’s body. In an August 20, 2015 press conference, his doctor revealed the melanoma had spread to four parts of his brain. The politician-turned-humanitarian had a history of cancer in his family. Carter’s parents and three siblings (two sisters and a brother) all died of different forms of cancer. His mother died of breast cancer; his father and siblings all died of pancreatic cancer. Age 90 at the time of his melanoma diagnosis, Carter believed he was nearing the end of his life but was at peace. “I just thought I had a few weeks left, but I was surprisingly at ease,” he said at the time, per ABC News . “I’ve had a wonderful life. I have thousands of friends...so I was surprisingly at ease, much more so than my wife was.” The former president underwent treatment (surgery, radiation therapy, and immunotherapy) to “extend” his life as much as possible. The treatment was successful, with Carter announcing in March 2016 that doctors stopped his treatment. Carter was hospitalized again the next year for dehydration due to building homes for Habitat for Humanity in Winnipeg, Canada. He was back at work on the homes the next day after some hours of observation. In May 2019, Carter broke his hip in a fall on his way out of his Plains, Georgia, home to go turkey hunting. He had a hip replacement a few days later and suffered another fall in October 2016, needing stitches over one of his eyebrows. In November 2019, he underwent surgery to address pressure in his brain caused by bleeding from the falls and recovered fine. Carter first served as a Georgia senator from 1963 to 1967 and then served as the 76th governor of Georgia from 1971 to 1975. He beat incumbent President Gerald Ford in the 1976 presidential election. The 2002 Nobel Peace Prize winner sought to make the government “competent and compassionate” during his tenure. His accomplishments as president include creating the Department of Education, bolstering the Social Security system, hiring a record number of minority groups in government jobs, and protecting/improving the environment. Part of that effort was successfully adding 103 million acres of Alaskan land to the national park system. Carter was determined to see the U.S. switch from fossil fuel to clean energy with renewable resources. To that end, he had 32 solar panels installed on the roof of the West Wing in the summer of 1979, hoping to set an example for the future of renewable energy. The panels were used for seven years before Reagan had them removed. While he had notable accomplishments, rising energy costs, mounting inflation, and continuing tensions made it difficult for Carter to meet the high expectations he set for his administration. He shepherded in nearly eight million new jobs and a decrease in the budget deficit (per WhiteHouse.org ), but near record-high inflation and interest rates of the time, and the efforts to fix them, triggered a short recession in the economy. In foreign affairs, Carter led the Camp David Accords in 1978, a political agreement between Egypt and Israel reached through 12 days of secret negotiations at the President’s Maryland country retreat. His focus on human rights didn’t sit well with the leaders of the Soviet Union and some other nations. He obtained ratification of the Panama Canal treaties, set up diplomatic relations with the People’s Republic of China, and finished the negotiation of the SALT II nuclear limitation treaty with the Soviet Union. Born James Earl Carter, Jr. on October 1, 1924, Carter’s family ran a peanut farm in Plains, Georgia. Talk of politics and his Baptist faith were tenets of his childhood. He graduated from the Naval Academy in Annapolis, Maryland, in 1946, serving seven years as a naval officer. Carter married his wife, Rosalynn Carter — who died in November 2023 — after graduating from the Academy in 1946. They share three sons, John William (Jack), James Earl III (Chip), Donnel Jeffrey (Jeff), and a daughter, Amy Lynn. Carter became a career politician in 1962 when elected to the Georgia State Senate. After his presidency, Carter focused his public efforts on humanitarian aid. He won the Nobel Peace Prize in 2002 “for his decades of untiring effort to find peaceful solutions to international conflicts, to advance democracy and human rights, and to promote economic and social development.” More Headlines:

Lampkin, Freeman power Syracuse past Bucknell, 75-63 in final nonconference tune-up